RSLS Key Statistics, Chart & Performance
The current stock price of RSLS is 3.92 USD. In the past month the price increased by 37.54%. In the past year, price decreased by -98.49%.
RSLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.11 | 217.86B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.78 | 200.77B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.32 | 141.35B | ||
| SYK | STRYKER CORP | 26.69 | 134.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.46 | 55.39B | ||
| IDXX | IDEXX LABORATORIES INC | 53.65 | 54.02B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.17 | 49.47B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.87 | 37.36B | ||
| RMD | RESMED INC | 24.33 | 35.16B | ||
| DXCM | DEXCOM INC | 35.68 | 25.89B | ||
| PODD | INSULET CORP | 62.2 | 20.00B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.82B |
Related stock screener links
About RSLS
Company Profile
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Company Info
RESHAPE LIFESCIENCES INC
1001 Calle Amanecer
San Clemente CALIFORNIA 92673 US
CEO: Andrew Rasdal
Employees: 17
Phone: 19494296680
RESHAPE LIFESCIENCES INC / RSLS FAQ
What does RSLS do?
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
What is the stock price of RESHAPE LIFESCIENCES INC today?
The current stock price of RSLS is 3.92 USD. The price increased by 22.5% in the last trading session.
Does RSLS stock pay dividends?
RSLS does not pay a dividend.
How is the ChartMill rating for RESHAPE LIFESCIENCES INC?
RSLS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is RESHAPE LIFESCIENCES INC (RSLS) stock traded?
RSLS stock is listed on the Nasdaq exchange.
RSLS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RSLS. When comparing the yearly performance of all stocks, RSLS is a bad performer in the overall market: 99.02% of all stocks are doing better.
RSLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RSLS. RSLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RSLS Financial Highlights
Over the last trailing twelve months RSLS reported a non-GAAP Earnings per Share(EPS) of -212.11. The EPS increased by 93.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.42% | ||
| ROE | -281.54% | ||
| Debt/Equity | 0 |
RSLS Forecast & Estimates
For the next year, analysts expect an EPS growth of 20% and a revenue growth 20% for RSLS